- Home
- QRVO vs TGTX Comparison
QRVO vs TGTX Comparison
Compare QRVO & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QRVO
- TGTX
- Stock Information
- Founded
- QRVO 1957
- TGTX 1993
- Country
- QRVO United States
- TGTX United States
- Employees
- QRVO N/A
- TGTX N/A
- Industry
- QRVO Semiconductors
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- QRVO Technology
- TGTX Health Care
- Exchange
- QRVO Nasdaq
- TGTX Nasdaq
- Market Cap
- QRVO 6.3B
- TGTX 5.4B
- IPO Year
- QRVO 1997
- TGTX 1995
- Fundamental
- Price
- QRVO $70.85
- TGTX $32.20
- Analyst Decision
- QRVO Hold
- TGTX Strong Buy
- Analyst Count
- QRVO 18
- TGTX 6
- Target Price
- QRVO $96.31
- TGTX $40.67
- AVG Volume (30 Days)
- QRVO 3.4M
- TGTX 2.2M
- Earning Date
- QRVO 01-29-2025
- TGTX 11-04-2024
- Dividend Yield
- QRVO N/A
- TGTX N/A
- EPS Growth
- QRVO N/A
- TGTX N/A
- EPS
- QRVO N/A
- TGTX N/A
- Revenue
- QRVO $3,948,029,000.00
- TGTX $264,790,000.00
- Revenue This Year
- QRVO N/A
- TGTX $43.74
- Revenue Next Year
- QRVO $4.55
- TGTX $64.30
- P/E Ratio
- QRVO N/A
- TGTX N/A
- Revenue Growth
- QRVO 26.11
- TGTX 39.53
- 52 Week Low
- QRVO $64.54
- TGTX $12.84
- 52 Week High
- QRVO $130.99
- TGTX $36.84
- Technical
- Relative Strength Index (RSI)
- QRVO 47.96
- TGTX 51.73
- Support Level
- QRVO $68.10
- TGTX $30.41
- Resistance Level
- QRVO $70.84
- TGTX $35.03
- Average True Range (ATR)
- QRVO 2.31
- TGTX 1.80
- MACD
- QRVO 0.85
- TGTX -0.46
- Stochastic Oscillator
- QRVO 87.28
- TGTX 35.31
About QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.